Akademik Veri Yönetim Sistemi
Applications of Chemistry in Nanosciences and Biomaterials Engineering NanoBioMat 2024 – Summer Edition, Bucuresti, Romanya, 19 - 21 Haziran 2024, ss.48-49
Over 50 million people worldwide suffer from epilepsy, a persistent neurological disorder. This disorder
arises from abnormal electrical activity that can target a specific region or the entire brain. Reducing seizure
frequency and intensity while lowering medication-induced brain and other tissue damage is the main
objective of epilepsy treatment. Antiepileptic drugs (AEDs) are commonly administered orally or
intravenously, yet these treatments may not always yield desired results. The blood-brain barrier, which
prevents AEDs from entering and staying in the brain, is one of the biological processes that severely limits
drug access to the brain.(1) Patients who do not respond to AEDs are classified as having drug-resistant
epilepsy, contributing substantially to the global epilepsy burden, with approximately 25% of epilepsy cases
being drug-resistant.
This strategy has gained popularity as a viable option in recent years because to the increased interest
in administering medications directly to the specific area of the brain where seizures take place. One method
involves creating polymeric implants loaded with drug, which can be precisely administered to the seizure
site for controlled and targeted delivery. By utilizing this localized drug delivery system, AEDs can be
effectively directed to the brain parenchyma, bypassing the blood-brain barrier (BBB) to achieve higher
drug concentrations at the seizure focus while minimizing systemic side effects. In this paper ethosuximide
(ETHX), a commonly used AED, is selected as active ingredient of implantable drug delivery system at
different amounts (10, 12.5, 15 mg)(2). In order to improve the releasing mechanism for an intracranial
administration, the poly(ε)caprolactone (PCL) scaffolds (25% w/v) with different pore sizes were produced
by 3D printing. Additionally, bismuth ferrite (BFO), synthesized via co-precipitation method, is added to
PCL scaffolds at amount of 3.75 mg to facilitate controlled drug release under electrical stimulation.
Tensile testing, differential scanning calorimetry (DSC), scanning electron microscopy (SEM), and
fourier transform infrared spectroscopy (FTIR) were used to assess the 3D-printed scaffolds that were created. The human neuroblastoma cell line (SH-SY5Y) was used in MTT experiments to demonstrate the
scaffolds' biocompatibility(3). Furthermore, in comparison to traditional drug-release methods, electrically
conductive 3D-printed scaffolds improved the drug release capabilities by showing that ETHX may be
released much faster by applying the electric field.